Nteliopoulos, Georgios
Page, Karen
Hills, Allison
Howarth, Karen
Emmett, Warren
Green, Emma
Martinson, Luke J.
Fernadez-Garcia, Daniel
Hastings, Robert
Guttery, David S.
Kenny, Laura
Stebbing, Justin
Cleator, Susan
Rehman, Farah
Gleason, Kelly L. T.
Sanela, Andrijac
Ion, Charlotte
Rushton, Amelia J.
Rosenfeld, Nitzan
Coombes, R. Charles
Shaw, Jacqueline A. http://orcid.org/0000-0003-4227-503X
Funding for this research was provided by:
CRUK (C14315/A23464)
Article History
Received: 17 November 2020
Accepted: 30 March 2021
First Online: 7 June 2021
Declarations
:
: KH, WE, EG and NR are current or former employees, officers, consultants and/or share-holders of Inivata Ltd or Inivata Inc. R.C. Coombes reports speaker frees from Pfizer and has shares in Carrick Ltd. L. Kenny reports receiving speakers bureau honoraria from Pfizer, and is a consultant/advisory board member for Celgene, Novartis, and Lilly. J. Stebbing is the Editor-in-Chief of Oncogene, sat on SABs for Celltrion, Vor Biopharma and Benevolent AI, and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. All the other authors declare that they have no competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Wales Multicenter Research Ethics Committee (MREC) (Imperial College Healthcare NHS Trust; Tissue Bank application number: R11015-20A; ICHTB HTA licence: 12275; REC Wales approval: 17/WA/0161).
: Informed consent was obtained from all individual participants included in the study.